Market Place
Sourcing Support
QurAlis Reports Ph1 Data On QRL-101 Biomarkers In ALS, Epilepsy
12 Mar 2025 //
PR NEWSWIRE
QurAlis` Trial of QRL-201 in ALS Advances to Dose Finding Phase
19 Nov 2024 //
PR NEWSWIRE
QurAlis Adds Williamson As CMO, Brown As CFO, Virani To Board
11 Jun 2024 //
PR NEWSWIRE
QurAlis Grants Lilly Exclusive Global License For QRL-204 In ALS, FTD
03 Jun 2024 //
PR NEWSWIRE
QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A
06 Sep 2023 //
PR NEWSWIRE
QurAlis, Unlearn link to use machine learning in ALS research
28 Jun 2023 //
FIERCE BIOTECH
QurAlis` FlexASOs Show High Potency and Improved Safety Over Standard ASOs
08 Jun 2023 //
PR NEWSWIRE
QurAlis receives authorisation to initiate ALS therapy trial in EU
07 Jun 2023 //
CLINICAL TRIALS ARENA
QurAlis Receives CTA in EU for QRL-201
06 Jun 2023 //
PR NEWSWIRE
QurAlis to Participate in Upcoming Investor Conferences in June
01 Jun 2023 //
PR NEWSWIRE
QurAlis enters ALS space with precision therapy approach
07 Apr 2023 //
CLINICAL TRIALS ARENA
QurAlis Reveals Program Targeting UNC13A RNA Incorporating its FlexASO Platform
20 Mar 2023 //
PR NEWSWIRE
QurAlis Closes $88M Series B Financing to Advance Precision Medicines
09 Mar 2023 //
PR NEWSWIRE
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
09 Mar 2023 //
ENDPTS
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101
05 Jan 2023 //
PR NEWSWIRE
Health Canada grants CTA authorisation for QurAlis’ ALS therapy
09 Dec 2022 //
CLINICALTRIALSARENA
QurAlis to Present at 22nd Annual Biotech in Europe Forum
13 Sep 2022 //
PRNEWSWIRE
QurAlis to Present at H.C. Wainwright Private Company Showcase
27 Jul 2022 //
PRNEWSWIRE
QurAlis to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
22 Mar 2022 //
PRNEWSWIRE
QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology & TDP-43
15 Mar 2022 //
PRNEWSWIRE
QurAlis Hires Key Regulatory Affairs, Clinical Operations, Global SCM Experts
08 Feb 2022 //
PRNEWSWIRE
Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel
08 Jun 2021 //
BUSINESSWIRE
QurAlis` Selective Kv7 Opener, a Drug Candidate for ALS, up to 20-Fold
11 Dec 2020 //
BUSINESSWIRE
QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1)
02 Dec 2020 //
BUSINESSWIRE
QurAlis Strengthens ALS Pipeline with Candidates from Lilly
02 Jul 2020 //
GLOBALNEWS
2 months after launch, QurAlis nabs early ALS compounds from Eli Lilly
01 Jul 2020 //
FIERCEBIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.